Patents by Inventor Robert George Edward Holgate

Robert George Edward Holgate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10874738
    Abstract: Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: December 29, 2020
    Assignee: IMMUNEXT INC.
    Inventors: Jay Rothstein, Robert George Edward Holgate, Arron Hearn
  • Publication number: 20200207854
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: February 25, 2020
    Publication date: July 2, 2020
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • Publication number: 20200181262
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 11, 2020
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • Patent number: 10626175
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: April 21, 2020
    Assignee: SYNTIMMUNE, INC.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan Dana Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • Publication number: 20190352395
    Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Application
    Filed: February 28, 2019
    Publication date: November 21, 2019
    Applicant: Redwood Bioscience, Inc.
    Inventors: David RABUKA, Robert George Edward HOLGATE, Francis Joseph CARR
  • Publication number: 20190300623
    Abstract: An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: (SEQ ID NO: 33) CDR1: EYTIH (SEQ ID NO: 34) CDR2: NINPNX1GGTTYNQKFED (SEQ ID NO: 35) CDR3: X2-5DY wherein X1 is N or Q, and X2-5 is YWLF, GWTF or AWTM, and wherein if X2-5 is GWTF or AWTM, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if X2-5 is YWLF, the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer.
    Type: Application
    Filed: August 18, 2017
    Publication date: October 3, 2019
    Inventors: Robert George Edward Holgate, Arron Robert Hearn
  • Publication number: 20190144562
    Abstract: An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequence given in SEQ ID NO:33, wherein SEQ ID NO:33 is: EVQLVQSGX9E X11KKPGASVKV SCKX24SGYTFT EYTIHWVX38QA X41 GKGLEWIGN INPNX55GGTTY NOKFEDRX68TX70 TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGOGTT VTVSS wherein: X9 is A or P X11 is V or L X24 is A or T X38 is R or K X41 is P or H X55 is N or Q X68 is V or A; and X70 is I or L whereby the heavy chain variable domain comprises up to 3 amino acid sequence modification(s) between positions 1-30, 36-49, 67-98 and 105-115 of SEQ ID NO: 33. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer.
    Type: Application
    Filed: June 6, 2017
    Publication date: May 16, 2019
    Inventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr
  • Patent number: 10259871
    Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 16, 2019
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
  • Publication number: 20180371066
    Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragments are administered under conditions and in an amount effective to prevent or treat the tauopathy.
    Type: Application
    Filed: March 23, 2018
    Publication date: December 27, 2018
    Inventors: Tim WEST, Diljeet S. Athwal, Timothy D. JONES, Francis J. CARR, Robert George Edward HOLGATE
  • Publication number: 20180291101
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: November 13, 2017
    Publication date: October 11, 2018
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan Dana Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • Publication number: 20180251534
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Inventors: Richard A. Fisher, Robert George Edward Holgate, Francis Joseph Carr, Timothy David Jones
  • Publication number: 20180193454
    Abstract: Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
    Type: Application
    Filed: July 13, 2016
    Publication date: July 12, 2018
    Inventors: Jay Rothstein, Robert George Edward Holgate, Arron Hearn
  • Patent number: 9988444
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 5, 2018
    Assignee: PROCLARA BIOSCIENCES, INC.
    Inventors: Richard A. Fisher, Robert George Edward Holgate, Francis Joseph Carr, Timothy David Jones
  • Patent number: 9957317
    Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: May 1, 2018
    Assignee: C2N Diagnostics, LLC
    Inventors: Tim West, Diljeet S. Athwal, Timothy D. Jones, Francis J. Carr, Robert George Edward Holgate
  • Publication number: 20180057595
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.
    Type: Application
    Filed: March 15, 2016
    Publication date: March 1, 2018
    Applicant: Celldex Therapeutics, Inc.
    Inventors: Yan Yang, Sreekala Mandiyan, Brett Robinson, Lida Kimmel, Yaron Hadari, Timothy David Jones, Francis Joseph Carr, Robert George Edward Holgate, Richard Weldon
  • Patent number: 9714290
    Abstract: The invention provides an anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7, in particular, it inhibits binding of CTLA4 to human B7.1 and/or human B7.2. Specific antibodies are provided with specific variable region sequences as well as compositions comprising such antibodies for use in treating disease.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: July 25, 2017
    Assignee: ANTITOPE LIMITED
    Inventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr
  • Publication number: 20170129945
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Application
    Filed: May 28, 2014
    Publication date: May 11, 2017
    Inventors: Richard A. FISHER, Robert George Edward HOLGATE, Francis Joseph CARR, Timothy David JONES
  • Publication number: 20170058024
    Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.
    Type: Application
    Filed: September 6, 2016
    Publication date: March 2, 2017
    Inventors: Tim West, Diljeet S. Athwal, Timothy D. Jones, Francis J. Carr, Robert George Edward Holgate
  • Publication number: 20160229911
    Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Application
    Filed: October 8, 2015
    Publication date: August 11, 2016
    Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
  • Publication number: 20160115223
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 28, 2016
    Inventors: Richard A. FISHER, Robert George, Edward HOLGATE, Francls Joseph CARR, Timothy David JONES